<DOC>
	<DOCNO>NCT00088101</DOCNO>
	<brief_summary>The purpose study determine safety , toxicity patient tolerance STA-5312 administer intravenously patient relapse refractory hematological malignancy patient solid tumor .</brief_summary>
	<brief_title>STA-5312 Administered Alternate Weekdays Every Two Weeks Patients With Hematologic Malignancies Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male female patient 18 year old one follow malignancy : Histologically cytologically confirm hematological malignancy ( Acute Myeloid Leukemia Myelodysplastic Syndrome ) treatment medically indicate , , Histologicallyconfirmed nonhematological malignancy metastatic unresectable standard therapy available . Patients CLL , PLL , CML , CTCL , ATL , NonHodgkin 's Lymphoma may enter refractory relapse follow conventional chemotherapy regimens alkylating agent ( e.g . chlorambucil cyclophosphamide ) , anthracycline combination [ e.g . CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) ] , and/or purine analogue ( e.g . fludarabine monophosphate 2CDA ) currently consider retreatment conventional regimen Patients CLL leukemic malignancy stag accord modify Rai stag criterion [ lowrisk , intermediaterisk high risk ] . All patient highrisk group ( Stage III IV ) eligible . Intermediate risk patient ( Stage I II ) one criterion active disease ( progressive lymphocytosis , lymphadenopathy , splenomegaly , weight loss &gt; 10 % within 6 month , extreme fatigue , fever and/or night sweat without evidence infection , etc . ) also eligible ECOG Performance Status 02 Life expectancy great 12 week . Patients must acceptable organ marrow function screen predose visit define unless approve medically clinical investigator . Absolute neutrophils count great 1,000 cells/ul patient hematologic malignancy â‰¥1,500 cells/ul patient solid tumor Platelets great 100,000/ul Hgb great 8.5 g/dL Total bilirubin must &lt; 1.5 mg/dL &lt; 2X upper limit normal AST ( SGOT ) &lt; 2.5 time upper limit normal ALT ( SGPT ) &lt; 2.5 time upper limit normal Adequate renal function ( serum creatinine &lt; 2.0 mg/dL calculate creatinine clearance great 50 mL/min ) Electrocardiogram without evidence clinically significant conduction abnormality active ischemia determine investigator . NCI grade 01 leave ventricular ejection fraction within 30 day dose . The effect STA5312 develop human fetus unknown . Therefore , woman childbearing potential ( defined woman 50 year age history amenorrhea &lt; 12 month prior study entry ) must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should female patient become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Women pregnant lactating . Patients chemotherapy , radiotherapy ( except palliative radiation deliver &lt; 20 % bone marrow ) , immunotherapy , corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 4 week prior enter study recover adverse event due agent administer 4 week earlier . The use nitrosoureas mitomycin C within 6 week prior study entry . Patients prior peripheral blood stem cell rescue bone marrow transplantation . History primary brain tumor active brain metastasis . ( Patients previously treat brain metastasis receive corticosteroid anticonvulsant may consider enrollment ) History stroke significant neurologic limitation within 6 month prior study enrollment Use investigational agent within 4 week study enrollment . History severe allergic reaction excipients ( e.g . Tween 80 ) hypersensitivity reaction chemotherapeutic agent similar structure STA5312 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement , determine investigator . History active CNSlymphoma , AIDSrelated lymphoma , uncontrolled severe medical illness infection . Grade 2 high sensory motor neuropathy screening . Major surgery ( exclude diagnosis ) within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Unresectable solid tumor</keyword>
</DOC>